{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:43:04Z","timestamp":1787496184581,"version":"build-2736575974"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"President of the Turkish Health Institutes","award":["32126"],"award-info":[{"award-number":["32126"]}]},{"name":"President of the Turkish Health Institutes","award":["32126"],"award-info":[{"award-number":["32126"]}]},{"name":"President of the Turkish Health Institutes","award":["32126"],"award-info":[{"award-number":["32126"]}]},{"DOI":"10.13039\/100032477","name":"Alanya Alaaddin Keykubat University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032477","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neurodegenerative diseases (ND), marked by progressive neuronal degeneration, often involve dysregulation of acetylcholinesterase (AChE), a key enzyme in cholinergic neurotransmission. AChE inhibition is a well-established therapeutic strategy for Alzheimer\u2019s disease (AD), the most prevalent ND, as it aims to restore impaired cholinergic function. However, the effects of calcineurin inhibitors (CNIs), primarily used as immunosuppressants, on AChE activity remain largely unexplored. Recent evidence suggests CNIs possess neuroprotective properties, highlighting their potential for ND treatment. This study evaluated the binding affinities of FDA-approved CNIs\u2014Tacrolimus (Tac), Pimecrolimus (Pim), Cyclosporine A (Csa), and Voclosporin (Voc)\u2014to AChE via molecular docking and molecular dynamic simulation. AChE inhibition was assessed in vitro using the Ellman method and in H\n                    <jats:sub>2<\/jats:sub>\n                    O\n                    <jats:sub>2<\/jats:sub>\n                    -induced degenerative neuron-like SH-SY5Y cells via ELISA and qRT-PCR. Neuroprotection was examined through MTT assays and neurite analysis. Additionally, the antiapoptotic effect was examined by ELISA analysis measuring caspase-3. Docking studies confirmed strong AChE binding for all CNIs, with Voc exhibiting the highest affinity. Voc demonstrated superior in vitro AChE inhibition, surpassing galantamine at low concentrations. Cellular assays showed that CNIs, particularly Voc, significantly inhibited AChE expression at the gene level. Moreover, Voc markedly restored cell viability and reduced neuronal degeneration in H\n                    <jats:sub>2<\/jats:sub>\n                    O\n                    <jats:sub>2<\/jats:sub>\n                    -treated cells. These findings suggest CNIs, especially Voc, as promising candidates for ND treatment, targeting AChE overactivity and oxidative stress.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\n                    Created in BioRender. Hamiyet\u00a0Eciroglu\u00a0Sarban, (2025)\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/BioRender.com\/q77r137\" ext-link-type=\"uri\">https:\/\/BioRender.com\/q77r137<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1007\/s12035-025-05149-0","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:36:03Z","timestamp":1757910963000},"page":"16592-16616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the Neuroprotective and Acetylcholinesterase Inhibitory Properties of Four Calcineurin Inhibitor Drugs: Tacrolimus, Pimecrolimus, Cyclosporin A, and Voclosporin"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-7933","authenticated-orcid":false,"given":"Fatma Gonca","family":"Kocanci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3555-3946","authenticated-orcid":false,"given":"Hamiyet Eciroglu","family":"Sarban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9270-9062","authenticated-orcid":false,"given":"Fatma","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"5149_CR1","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/alz.12127","volume":"16","author":"BCM Stephan","year":"2020","unstructured":"Stephan BCM, Siervo M, Brayne C (2020) How can population-based studies best be utilized to reduce the global impact of dementia? Recommendations for researchers, funders, and policymakers. Alzheimer\u2019s & Dementia 16:1448\u20131456. https:\/\/doi.org\/10.1002\/alz.12127","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"5149_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.disamonth.2010.06.001","volume":"56","author":"RJ Castellani","year":"2010","unstructured":"Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer Disease. Dis Mon 56:484\u2013546. https:\/\/doi.org\/10.1016\/j.disamonth.2010.06.001","journal-title":"Dis Mon"},{"key":"5149_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/archneur.56.6.673","volume":"56","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Hesse C, Davidsson P et al (1999) Cerebrospinal Fluid \u03b2-Amyloid(1\u201342) in alzheimer disease: differences between early- and late-onset alzheimer disease and stability during the course of disease. Arch Neurol 56:673\u2013680. https:\/\/doi.org\/10.1001\/archneur.56.6.673","journal-title":"Arch Neurol"},{"key":"5149_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer\u2019s disease. Lancet 368:387\u2013403. https:\/\/doi.org\/10.1016\/S0140-6736(06)69113-7","journal-title":"Lancet"},{"key":"5149_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/DNND.S452009","volume":"14","author":"PN Tripathi","year":"2024","unstructured":"Tripathi PN, Lodhi A, Rai SN et al (2024) Review of pharmacotherapeutic targets in Alzheimer\u2019s disease and its management using traditional medicinal plants. Degener Neurol Neuromuscul Dis 14:47\u201374. https:\/\/doi.org\/10.2147\/DNND.S452009","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"5149_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/319407a0","volume":"319","author":"M Schumacher","year":"1986","unstructured":"Schumacher M, Camp S, Maulet Y et al (1986) Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence. Nature 319:407\u2013409. https:\/\/doi.org\/10.1038\/319407a0","journal-title":"Nature"},{"key":"5149_CR7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.neubiorev.2011.03.001","volume":"35","author":"L Craig","year":"2011","unstructured":"Craig L, Hong N, McDonald R (2011) Revisiting the cholinergic hypothesis in the development of Alzheimer\u2019s disease. Neurosci Biobehav Rev 35:1397\u20131409. https:\/\/doi.org\/10.1016\/j.neubiorev.2011.03.001","journal-title":"Neurosci Biobehav Rev"},{"key":"5149_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0011-393X(03)00059-6","volume":"64","author":"GT Grossberg","year":"2003","unstructured":"Grossberg GT (2003) Cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease. Curr Ther Res Clin Exp 64:216\u2013235. https:\/\/doi.org\/10.1016\/S0011-393X(03)00059-6","journal-title":"Curr Ther Res Clin Exp"},{"key":"5149_CR9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","volume":"367","author":"B Singh","year":"2024","unstructured":"Singh B, Day CM, Abdella S, Garg S (2024) Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release 367:402\u2013424. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.047","journal-title":"J Control Release"},{"key":"5149_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bioorg.2018.12.017","volume":"85","author":"PN Tripathi","year":"2019","unstructured":"Tripathi PN, Srivastava P, Sharma P et al (2019) Biphenyl-3-oxo-1,2,4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorg Chem 85:82\u201396. https:\/\/doi.org\/10.1016\/j.bioorg.2018.12.017","journal-title":"Bioorg Chem"},{"key":"5149_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejmech.2018.11.049","volume":"163","author":"P Srivastava","year":"2019","unstructured":"Srivastava P, Tripathi PN, Sharma P et al (2019) Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Eur J Med Chem 163:116\u2013135. https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.049","journal-title":"Eur J Med Chem"},{"key":"5149_CR12","doi-asserted-by":"publisher","unstructured":"Ramakrishna K, Karuturi P, Siakabinga Q et al (2024) Indole-3 carbinol and diindolylmethane mitigated \u03b2-amyloid-induced neurotoxicity and acetylcholinesterase enzyme activity: in silico, in vitro, and network pharmacology study. Diseases 12:184. https:\/\/doi.org\/10.3390\/diseases12080184","DOI":"10.3390\/diseases12080184"},{"key":"5149_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jalz.2016.12.006","volume":"13","author":"AACH Workgroup","year":"2017","unstructured":"Workgroup AACH, Khachaturian ZS (2017) Calcium hypothesis of Alzheimer\u2019s disease and brain aging: a framework for integrating new evidence into a comprehensive theory of pathogenesis. Alzheimer\u2019s & Dementia 13:178-182.e17. https:\/\/doi.org\/10.1016\/j.jalz.2016.12.006","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"5149_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.bbrc.2004.06.070","volume":"320","author":"DH O\u2019Day","year":"2004","unstructured":"O\u2019Day DH, Myre MA (2004) Calmodulin-binding domains in Alzheimer\u2019s disease proteins: extending the calcium hypothesis. Biochem Biophys Res Commun 320:1051\u20131054. https:\/\/doi.org\/10.1016\/j.bbrc.2004.06.070","journal-title":"Biochem Biophys Res Commun"},{"key":"5149_CR15","doi-asserted-by":"publisher","first-page":"12957","DOI":"10.1523\/JNEUROSCI.1064-09.2009","volume":"29","author":"HM Abdul","year":"2009","unstructured":"Abdul HM, Sama MA, Furman JL et al (2009) Cognitive decline in Alzheimer\u2019s disease is associated with selective changes in calcineurin\/NFAT signaling. J Neurosci 29:12957\u201312969. https:\/\/doi.org\/10.1523\/JNEUROSCI.1064-09.2009","journal-title":"J Neurosci"},{"key":"5149_CR16","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1016\/j.neurobiolaging.2015.09.007","volume":"36","author":"S Kim","year":"2015","unstructured":"Kim S, Violette CJ, Ziff EB (2015) Reduction of increased calcineurin activity rescues impaired homeostatic synaptic plasticity in presenilin 1 M146V mutant. Neurobiol Aging 36:3239\u20133246. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.09.007","journal-title":"Neurobiol Aging"},{"key":"5149_CR17","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1523\/JNEUROSCI.0365-05.2005","volume":"25","author":"CM Norris","year":"2005","unstructured":"Norris CM, Kadish I, Blalock EM et al (2005) Calcineurin triggers reactive\/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer\u2019s models. J Neurosci 25:4649. https:\/\/doi.org\/10.1523\/JNEUROSCI.0365-05.2005","journal-title":"J Neurosci"},{"key":"5149_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2174\/157015911798376316","volume":"9","author":"C. Reese L, Taglialatela G,","year":"2011","unstructured":"C. Reese L, Taglialatela G, (2011) A role for calcineurin in alzheimer\u2019s disease. Curr Neuropharmacol 9:685\u2013692. https:\/\/doi.org\/10.2174\/157015911798376316","journal-title":"Curr Neuropharmacol"},{"key":"5149_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1006\/exnr.2000.7534","volume":"167","author":"Q Lian","year":"2001","unstructured":"Lian Q, Ladner CJ, Magnuson D, Lee JM (2001) Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer\u2019s disease cerebral cortex. Exp Neurol 167:158\u2013165. https:\/\/doi.org\/10.1006\/exnr.2000.7534","journal-title":"Exp Neurol"},{"key":"5149_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.nlm.2007.03.010","volume":"88","author":"KT Dineley","year":"2007","unstructured":"Dineley KT, Hogan D, Zhang W-R, Taglialatela G (2007) Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem 88:217\u2013224. https:\/\/doi.org\/10.1016\/j.nlm.2007.03.010","journal-title":"Neurobiol Learn Mem"},{"key":"5149_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3233\/JAD-150065","volume":"47","author":"G Taglialatela","year":"2015","unstructured":"Taglialatela G, Rastellini C, Cicalese L (2015) Reduced incidence of dementia in solid organ transplant patients treated with calcineurin inhibitors. J Alzheimers Dis 47:329\u2013333. https:\/\/doi.org\/10.3233\/JAD-150065","journal-title":"J Alzheimers Dis"},{"key":"5149_CR22","doi-asserted-by":"publisher","unstructured":"Kocanci FG (2025) Effect of pimecrolimus on apoptotic pathways in H2O2-treated neuron like differentiated-SH-SY5Y cells: a molecular docking and mechanistic study.\u00a0Toxicol Res\u00a014:tfaf020. https:\/\/doi.org\/10.1093\/toxres\/tfaf020","DOI":"10.1093\/toxres\/tfaf020"},{"key":"5149_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13328","volume":"99","author":"FG Kocanci","year":"2024","unstructured":"Kocanci FG, Erol AYG, Yildiz F, Eciroglu H (2024) Pimecrolimus protects neuron-like SH-SY5Y cells against anti-inflammatory and anti-oxidant effects of both microglial secretome and hydrogen peroxide. Scand J Immunol 99:e13328. https:\/\/doi.org\/10.1111\/sji.13328","journal-title":"Scand J Immunol"},{"key":"5149_CR24","doi-asserted-by":"publisher","unstructured":"Kocanci FG, Goksu AY Anti-inflammatory and antioxidative actions of tacrolimus (FK506) on human microglial HMC3 cell line.\u00a0Scand J Immunol\u00a0n\/a:e13339. https:\/\/doi.org\/10.1111\/sji.13339","DOI":"10.1111\/sji.13339"},{"key":"5149_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.colsurfa.2018.07.005","volume":"555","author":"M Piotrowski","year":"2018","unstructured":"Piotrowski M, Jantas D, Le\u015bkiewicz M et al (2018) Polyelectrolyte-coated nanocapsules containing cyclosporine a protect neuronal-like cells against oxidative stress-induced cell damage. Colloids Surf, A 555:264\u2013269. https:\/\/doi.org\/10.1016\/j.colsurfa.2018.07.005","journal-title":"Colloids Surf, A"},{"key":"5149_CR26","doi-asserted-by":"publisher","first-page":"29605","DOI":"10.1074\/jbc.m109.039560","volume":"284","author":"H Hayashi","year":"2009","unstructured":"Hayashi H, Campenot RB, Vance DE, Vance JE (2009) Protection of neurons from apoptosis by apolipoprotein e-containing lipoproteins does not require lipoprotein uptake and involves activation of phospholipase C\u03b31 and inhibition of calcineurin. J Biol Chem 284:29605\u201329613. https:\/\/doi.org\/10.1074\/jbc.m109.039560","journal-title":"J Biol Chem"},{"key":"5149_CR27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1471-4159.2006.04136.x","volume":"99","author":"K Szydlowska","year":"2006","unstructured":"Szydlowska K, Zawadzka M, Kaminska B (2006) Neuroprotectant FK506 inhibits glutamate-induced apoptosis of astrocytes in vitro and in vivo. J Neurochem 99:965\u2013975. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04136.x","journal-title":"J Neurochem"},{"key":"5149_CR28","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1523\/jneurosci.18-14-05151.1998","volume":"18","author":"H Friberg","year":"1998","unstructured":"Friberg H, Ferrand-Drake M, Bengtsson F et al (1998) Cyclosporin a, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J Neurosci 18:5151\u20135159. https:\/\/doi.org\/10.1523\/jneurosci.18-14-05151.1998","journal-title":"J Neurosci"},{"key":"5149_CR29","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1046\/j.1460-9568.1999.00743.x","volume":"11","author":"L Khaspekov","year":"1999","unstructured":"Khaspekov L, Friberg H, Halestrap A et al (1999) Cyclosporin A and its nonimmunosuppressive analogue N-Me-Val-4-cyclosporin A mitigate glucose\/oxygen deprivation-induced damage to rat cultured hippocampal neurons. Eur J of Neuroscience 11:3194\u20133198. https:\/\/doi.org\/10.1046\/j.1460-9568.1999.00743.x","journal-title":"Eur J of Neuroscience"},{"key":"5149_CR30","doi-asserted-by":"publisher","first-page":"16129","DOI":"10.1523\/JNEUROSCI.2323-12.2012","volume":"32","author":"JL Furman","year":"2012","unstructured":"Furman JL, Sama DM, Gant JC et al (2012) Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer\u2019s disease. J Neurosci 32:16129\u201316140. https:\/\/doi.org\/10.1523\/JNEUROSCI.2323-12.2012","journal-title":"J Neurosci"},{"key":"5149_CR31","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1523\/jneurosci.6439-11.2012","volume":"32","author":"E Hudry","year":"2012","unstructured":"Hudry E, Wu H-Y, Arbel-Ornath M et al (2012) Inhibition of the NFAT pathway alleviates amyloid beta neurotoxicity in a mouse model of Alzheimer\u2019s disease. J Neurosci 32:3176\u20133192. https:\/\/doi.org\/10.1523\/jneurosci.6439-11.2012","journal-title":"J Neurosci"},{"key":"5149_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/jad-2010-100261","volume":"22","author":"H-S Hong","year":"2010","unstructured":"Hong H-S, Hwang J-Y, Son S-M et al (2010) FK506 reduces amyloid plaque burden and induces MMP-9 in A\u03b2PP\/PS1 double transgenic mice. JAD 22:97\u2013105. https:\/\/doi.org\/10.3233\/jad-2010-100261","journal-title":"JAD"},{"key":"5149_CR33","doi-asserted-by":"publisher","unstructured":"Fields JA, Overk C, Adame A, et al (2016) Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity. J Neuroinflammation 13:. https:\/\/doi.org\/10.1186\/s12974-016-0585-8","DOI":"10.1186\/s12974-016-0585-8"},{"key":"5149_CR34","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1523\/jneurosci.17-18-06939.1997","volume":"17","author":"SP Butcher","year":"1997","unstructured":"Butcher SP, Henshall DC, Teramura Y et al (1997) Neuroprotective Actions of FK506 in Experimental Stroke. In VivoEvidence against an Antiexcitotoxic Mechanism. J Neurosci 17:6939\u20136946. https:\/\/doi.org\/10.1523\/jneurosci.17-18-06939.1997","journal-title":"J Neurosci"},{"key":"5149_CR35","doi-asserted-by":"publisher","unstructured":"Zaichick S, Caraveo G (2023) Harnessing IGF-1 and IL-2 as biomarkers for calcineurin activity to tailor optimal FK506 dosage in \u03b1-synucleinopathies. Front Mol Biosci 10:. https:\/\/doi.org\/10.3389\/fmolb.2023.1292555","DOI":"10.3389\/fmolb.2023.1292555"},{"key":"5149_CR36","doi-asserted-by":"publisher","unstructured":"Caraveo G, Auluck PK, Whitesell L, et al (2014) Calcineurin determines toxic versus beneficial responses to \u03b1-synuclein. Proc Natl Acad Sci USA 111:. https:\/\/doi.org\/10.1073\/pnas.1413201111","DOI":"10.1073\/pnas.1413201111"},{"key":"5149_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ibneur.2024.02.001","volume":"16","author":"J-M Hong","year":"2024","unstructured":"Hong J-M, Munna AN, Moon J-H et al (2024) Melatonin-mediated calcineurin inactivation attenuates amyloid beta-induced apoptosis. IBRO Neuroscience Reports 16:336\u2013344. https:\/\/doi.org\/10.1016\/j.ibneur.2024.02.001","journal-title":"IBRO Neuroscience Reports"},{"key":"5149_CR38","doi-asserted-by":"publisher","unstructured":"Zaichick S, Grebenik E, Caraveo G (2025) Calcineurin-mediated regulation of growth-associated protein 43 is essential for neurite and synapse formation and protects against \u03b1-synuclein-induced degeneration. https:\/\/doi.org\/10.1101\/2025.01.13.632848","DOI":"10.1101\/2025.01.13.632848"},{"key":"5149_CR39","doi-asserted-by":"publisher","unstructured":"Zhang C, Liu X, Xu H et al (2020) Protopanaxadiol ginsenoside Rd protects against NMDA receptor-mediated excitotoxicity by attenuating calcineurin-regulated DAPK1 activity. Sci Rep 10:. https:\/\/doi.org\/10.1038\/s41598-020-64738-2","DOI":"10.1038\/s41598-020-64738-2"},{"key":"5149_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.therap.2020.02.006","volume":"75","author":"C Fetro","year":"2020","unstructured":"Fetro C, Scherman D (2020) Drug repurposing in rare diseases: myths and reality. Therapies 75:157\u2013160. https:\/\/doi.org\/10.1016\/j.therap.2020.02.006","journal-title":"Therapies"},{"key":"5149_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/23808993.2018.1424535","volume":"3","author":"A Talevi","year":"2018","unstructured":"Talevi A (2018) Drug repositioning: current approaches and their implications in the precision medicine era. Expert Rev Precis Med Drug Dev 3:49\u201361. https:\/\/doi.org\/10.1080\/23808993.2018.1424535","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"5149_CR42","doi-asserted-by":"publisher","first-page":"W159","DOI":"10.1093\/nar\/gkac394","volume":"50","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yang X, Gan J et al (2022) CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res 50:W159\u2013W164. https:\/\/doi.org\/10.1093\/nar\/gkac394","journal-title":"Nucleic Acids Res"},{"key":"5149_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijbiomac.2022.05.009","volume":"210","author":"KV Dileep","year":"2022","unstructured":"Dileep KV, Ihara K, Mishima-Tsumagari C et al (2022) Crystal structure of human acetylcholinesterase in complex with tacrine: Implications for drug discovery. Int J Biol Macromol 210:172\u2013181. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.05.009","journal-title":"Int J Biol Macromol"},{"key":"5149_CR44","doi-asserted-by":"publisher","first-page":"W623","DOI":"10.1093\/nar\/gkp456","volume":"37","author":"Y Wang","year":"2009","unstructured":"Wang Y, Xiao J, Suzek TO et al (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 37:W623-633. https:\/\/doi.org\/10.1093\/nar\/gkp456","journal-title":"Nucleic Acids Res"},{"key":"5149_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","volume":"7","author":"GL Ellman","year":"1961","unstructured":"Ellman GL, Courtney KD, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88\u201395. https:\/\/doi.org\/10.1016\/0006-2952(61)90145-9","journal-title":"Biochem Pharmacol"},{"key":"5149_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12974-016-0480-3","volume":"13","author":"H Cheng","year":"2016","unstructured":"Cheng H, Davis DA, Hasheminassab S et al (2016) Urban traffic-derived nanoparticulate matter reduces neurite outgrowth via TNF\u03b1 in vitro. J Neuroinflammation 13:19. https:\/\/doi.org\/10.1186\/s12974-016-0480-3","journal-title":"J Neuroinflammation"},{"key":"5149_CR47","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3892\/ijmm.2019.4139","volume":"43","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Spandidos DA, Tsatsakis A et al (2019) Neuroprotective effects of Scrophularia buergeriana extract against glutamate-induced toxicity in SH-SY5Y cells. Int J Mol Med 43:2144\u20132152. https:\/\/doi.org\/10.3892\/ijmm.2019.4139","journal-title":"Int J Mol Med"},{"key":"5149_CR48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0011-393X(03)00059-6","volume":"64","author":"G Grossberg","year":"2003","unstructured":"Grossberg G (2003) Cholinesterase Inhibitors for the Treatment of Alzheimer\u2019s Disease: Getting On and Staying On. Curr Ther Res 64:216\u2013235. https:\/\/doi.org\/10.1016\/S0011-393X(03)00059-6","journal-title":"Curr Ther Res"},{"key":"5149_CR49","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/TCRM.S323387","volume":"17","author":"S Ruangritchankul","year":"2021","unstructured":"Ruangritchankul S, Chantharit P, Srisuma S, Gray LC (2021) Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review. Ther Clin Risk Manag 17:927\u2013949. https:\/\/doi.org\/10.2147\/TCRM.S323387","journal-title":"Ther Clin Risk Manag"},{"key":"5149_CR50","doi-asserted-by":"publisher","unstructured":"Qizilbash N, Birks J, L\u00f3pez-Arrieta J et al (2007) WITHDRAWN: tacrine for Alzheimer\u2019s disease. Cochrane database of systematic reviews (Online) 18:CD000202. https:\/\/doi.org\/10.1002\/14651858.CD000202","DOI":"10.1002\/14651858.CD000202"},{"key":"5149_CR51","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bph.13798","volume":"175","author":"Y Cha","year":"2018","unstructured":"Cha Y, Erez T, Reynolds IJ et al (2018) Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol 175:168\u2013180. https:\/\/doi.org\/10.1111\/bph.13798","journal-title":"Br J Pharmacol"},{"key":"5149_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ceb.2010.12.006","volume":"23","author":"A Mukherjee","year":"2011","unstructured":"Mukherjee A, Soto C (2011) Role of calcineurin in neurodegeneration produced by misfolded proteins and endoplasmic reticulum stress. Curr Opin Cell Biol 23:223\u2013230. https:\/\/doi.org\/10.1016\/j.ceb.2010.12.006","journal-title":"Curr Opin Cell Biol"},{"key":"5149_CR53","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12974-014-0158-7","volume":"11","author":"JL Furman","year":"2014","unstructured":"Furman JL, Norris CM (2014) Calcineurin and glial signaling: neuroinflammation and beyond. J Neuroinflammation 11:158. https:\/\/doi.org\/10.1186\/s12974-014-0158-7","journal-title":"J Neuroinflammation"},{"key":"5149_CR54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1750-1326-4-20","volume":"4","author":"P Marambaud","year":"2009","unstructured":"Marambaud P, Dreses-Werringloer U, Vingtdeux V (2009) Calcium signaling in neurodegeneration. Mol Neurodegener 4:20. https:\/\/doi.org\/10.1186\/1750-1326-4-20","journal-title":"Mol Neurodegener"},{"key":"5149_CR55","unstructured":"Safarini OA, Keshavamurthy C, Patel P (2023) Calcineurin Inhibitors. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"5149_CR56","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.3390\/ijms22094914","volume":"22","author":"R Cascella","year":"2021","unstructured":"Cascella R, Cecchi C (2021) Calcium dyshomeostasis in Alzheimer\u2019s disease pathogenesis. Int J Mol Sci 22:4914. https:\/\/doi.org\/10.3390\/ijms22094914","journal-title":"Int J Mol Sci"},{"key":"5149_CR57","doi-asserted-by":"publisher","unstructured":"Mackiewicz J, Lisek M, Boczek T (2023) Targeting CaN\/NFAT in Alzheimer\u2019s brain degeneration. Front Immunol 14:. https:\/\/doi.org\/10.3389\/fimmu.2023.1281882","DOI":"10.3389\/fimmu.2023.1281882"},{"key":"5149_CR58","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3233\/JAD-230526","volume":"95","author":"JD Silva","year":"2023","unstructured":"Silva JD, Taglialatela G, Jupiter DC (2023) Reduced prevalence of dementia in patients prescribed tacrolimus, sirolimus, or cyclosporine. J Alzheimers Dis 95:585\u2013597. https:\/\/doi.org\/10.3233\/JAD-230526","journal-title":"J Alzheimers Dis"},{"key":"5149_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/alz.069099","volume":"18","author":"L Sordo","year":"2022","unstructured":"Sordo L, Ubele MF, Boaz K et al (2022) Effect of calcineurin inhibitors on cognition in a canine model of Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia 18:e069099. https:\/\/doi.org\/10.1002\/alz.069099","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"5149_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.pbb.2016.12.018","volume":"153","author":"A Kumar","year":"2017","unstructured":"Kumar A, Singh N (2017) Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia. Pharmacol Biochem Behav 153:147\u2013159. https:\/\/doi.org\/10.1016\/j.pbb.2016.12.018","journal-title":"Pharmacol Biochem Behav"},{"key":"5149_CR61","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1021\/acschemneuro.8b00213","volume":"9","author":"MA O\u2019Neal","year":"2018","unstructured":"O\u2019Neal MA, Stallings NR, Malter JS (2018) Alzheimer\u2019s Disease, dendritic spines, and calcineurin inhibitors: a new approach? ACS Chem Neurosci 9:1233\u20131234. https:\/\/doi.org\/10.1021\/acschemneuro.8b00213","journal-title":"ACS Chem Neurosci"},{"key":"5149_CR62","doi-asserted-by":"crossref","unstructured":"Regen F, Hellmann-Regen J, Costantini E, Reale M (2017) Neuroinflammation and Alzheimer\u2019s disease: implications for microglial activation. https:\/\/www.ingentaconnect.com\/content\/ben\/car\/2017\/00000014\/00000011\/art00003. Accessed 22 Jan 2025","DOI":"10.2174\/1567205014666170203141717"},{"key":"5149_CR63","unstructured":"Araya AA, Tasnif Y (2023) Tacrolimus. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"5149_CR64","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3390\/cells12222659","volume":"12","author":"MJ Smith","year":"2023","unstructured":"Smith MJ, Penny T, Pham Y et al (2023) Neuroprotective action of tacrolimus before and after onset of neonatal hypoxic-ischaemic brain injury in rats. Cells 12:2659. https:\/\/doi.org\/10.3390\/cells12222659","journal-title":"Cells"},{"key":"5149_CR65","first-page":"95","volume":"2","author":"B Kaminska","year":"2006","unstructured":"Kaminska B, Zawadzka M, Szydlowska K, Wisniewski P (2006) Anti-inflammatory and anti-cytotoxic action of neuroprotective immunosuppressants. Int J Neuroprot Neuroregener 2:95\u2013102","journal-title":"Int J Neuroprot Neuroregener"},{"key":"5149_CR66","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/brb3.16","volume":"1","author":"S Yousuf","year":"2011","unstructured":"Yousuf S, Atif F, Kesherwani V, Agrawal SK (2011) Neuroprotective effects of tacrolimus (FK-506) and cyclosporin (CsA) in oxidative injury. Brain Behav 1:87\u201394. https:\/\/doi.org\/10.1002\/brb3.16","journal-title":"Brain Behav"},{"key":"5149_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0006-8993(02)04151-3","volume":"965","author":"Y Furuichi","year":"2003","unstructured":"Furuichi Y, Katsuta K, Maeda M et al (2003) Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res 965:137\u2013145. https:\/\/doi.org\/10.1016\/S0006-8993(02)04151-3","journal-title":"Brain Res"},{"key":"5149_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13339","volume":"99","author":"FG Kocanci","year":"2024","unstructured":"Kocanci FG, Goksu AY (2024) Anti-inflammatory and antioxidative actions of tacrolimus (FK506) on human microglial HMC3 cell line. Scand J Immunol 99:e13339. https:\/\/doi.org\/10.1111\/sji.13339","journal-title":"Scand J Immunol"},{"key":"5149_CR69","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000524594","volume":"103","author":"S Nakata","year":"2022","unstructured":"Nakata S, Kakimoto K, Numa K et al (2022) Risk factors for nephrotoxicity due to tacrolimus therapy for ulcerative colitis. Digestion 103:339\u2013346. https:\/\/doi.org\/10.1159\/000524594","journal-title":"Digestion"},{"key":"5149_CR70","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1107\/S0907444994014514","volume":"51","author":"KP Wilson","year":"1995","unstructured":"Wilson KP, Yamashita MM, Sintchak MD et al (1995) Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin. Acta Crystallogr Sect D 51:511\u2013521. https:\/\/doi.org\/10.1107\/S0907444994014514","journal-title":"Acta Crystallogr Sect D"},{"key":"5149_CR71","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/pai.12331","volume":"26","author":"T Luger","year":"2015","unstructured":"Luger T, Boguniewicz M, Carr W et al (2015) Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol 26:306\u2013315. https:\/\/doi.org\/10.1111\/pai.12331","journal-title":"Pediatr Allergy Immunol"},{"key":"5149_CR72","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1046\/j.1468-3083.2003.00692.x","volume":"17","author":"A Gupta","year":"2003","unstructured":"Gupta A, Chow M (2003) Pimecrolimus: a review. J Eur Acad Dermatol Venereol 17:493\u2013503. https:\/\/doi.org\/10.1046\/j.1468-3083.2003.00692.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5149_CR73","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/jdv.17272","volume":"35","author":"T Luger","year":"2021","unstructured":"Luger T, Paller A, s., Irvine A d, et al (2021) Topical therapy of atopic dermatitis with a focus on pimecrolimus. J Eur Acad Dermatol Venereol 35:1505\u20131518. https:\/\/doi.org\/10.1111\/jdv.17272","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5149_CR74","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/0738-081X(89)90011-4","volume":"7","author":"AK Gupta","year":"1989","unstructured":"Gupta AK, Ellis CN, Goldfarb MT et al (1989) Cyclosporine A. Clin Dermatol 7:98\u2013110. https:\/\/doi.org\/10.1016\/0738-081X(89)90011-4","journal-title":"Clin Dermatol"},{"key":"5149_CR75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ams2.343","volume":"5","author":"S Matsumoto","year":"2018","unstructured":"Matsumoto S, Murozono M, Kanazawa M et al (2018) Edaravone and cyclosporine A as neuroprotective agents for acute ischemic stroke. Acute Med Surg 5:213\u2013221. https:\/\/doi.org\/10.1002\/ams2.343","journal-title":"Acute Med Surg"},{"key":"5149_CR76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fncel.2019.00273","volume":"13","author":"SJ Wowro","year":"2019","unstructured":"Wowro SJ, Tong G, Krech J et al (2019) Combined cyclosporin A and hypothermia treatment inhibits activation of BV-2 microglia but induces an inflammatory response in an ischemia\/reperfusion hippocampal slice culture model. Front Cell Neurosci 13:273. https:\/\/doi.org\/10.3389\/fncel.2019.00273","journal-title":"Front Cell Neurosci"},{"key":"5149_CR77","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.npep.2011.04.002","volume":"45","author":"MM Osman","year":"2011","unstructured":"Osman MM, Lulic D, Glover L et al (2011) Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application. Neuropeptides 45:359\u2013368. https:\/\/doi.org\/10.1016\/j.npep.2011.04.002","journal-title":"Neuropeptides"},{"key":"5149_CR78","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1006\/exnr.1999.7197","volume":"160","author":"PG Sullivan","year":"1999","unstructured":"Sullivan PG, Thompson MB, Scheff SW (1999) Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol 160:226\u2013234. https:\/\/doi.org\/10.1006\/exnr.1999.7197","journal-title":"Exp Neurol"},{"key":"5149_CR79","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40265-021-01488-z","volume":"81","author":"Y-A Heo","year":"2021","unstructured":"Heo Y-A (2021) Voclosporin: first approval. Drugs 81:605\u2013610. https:\/\/doi.org\/10.1007\/s40265-021-01488-z","journal-title":"Drugs"},{"key":"5149_CR80","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40262-023-01246-2","volume":"62","author":"E Abdel-Kahaar","year":"2023","unstructured":"Abdel-Kahaar E, Keller F (2023) Clinical pharmacokinetics and pharmacodynamics of voclosporin. Clin Pharmacokinet 62:693\u2013703. https:\/\/doi.org\/10.1007\/s40262-023-01246-2","journal-title":"Clin Pharmacokinet"},{"key":"5149_CR81","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3390\/biom10030414","volume":"10","author":"SF de Cavalcante","year":"2020","unstructured":"de Cavalcante SF, A, Simas ABC, Barcellos MC et al (2020) Acetylcholinesterase: The \u201cHub\u201d for neurodegenerative diseases and chemical weapons convention. Biomolecules 10:414. https:\/\/doi.org\/10.3390\/biom10030414","journal-title":"Biomolecules"},{"key":"5149_CR82","doi-asserted-by":"publisher","first-page":"9031","DOI":"10.1073\/pnas.90.19.9031","volume":"90","author":"M Harel","year":"1993","unstructured":"Harel M, Schalk I, Ehret-Sabatier L et al (1993) Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A 90:9031\u20139035","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5149_CR83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cbi.2010.01.042","volume":"187","author":"H Dvir","year":"2010","unstructured":"Dvir H, Silman I, Harel M et al (2010) Acetylcholinesterase: from 3D structure to function. Chem Biol Interact 187:10\u201322. https:\/\/doi.org\/10.1016\/j.cbi.2010.01.042","journal-title":"Chem Biol Interact"},{"key":"5149_CR84","doi-asserted-by":"publisher","unstructured":"Berg L, Andersson CD, Artursson E et al (2011) Targeting\u00a0acetylcholinesterase: identification of chemical leads by high throughput screening, structure determination and molecular modeling. PLoS ONE 6. https:\/\/doi.org\/10.1371\/journal.pone.0026039","DOI":"10.1371\/journal.pone.0026039"},{"key":"5149_CR85","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuro.2022.07.008","volume":"92","author":"L Lopez-Suarez","year":"2022","unstructured":"Lopez-Suarez L, Awabdh SA, Coumoul X, Chauvet C (2022) The SH-SY5Y human neuroblastoma cell line, a relevant in vitro cell model for investigating neurotoxicology in human: focus on organic pollutants. Neurotoxicology 92:131\u2013155. https:\/\/doi.org\/10.1016\/j.neuro.2022.07.008","journal-title":"Neurotoxicology"},{"key":"5149_CR86","doi-asserted-by":"publisher","first-page":"7355","DOI":"10.1007\/s12035-019-1605-3","volume":"56","author":"LM de Medeiros","year":"2019","unstructured":"de Medeiros LM, De Bastiani MA, Rico EP et al (2019) Cholinergic differentiation of human neuroblastoma SH-SY5Y cell line and its potential use as an in vitro model for Alzheimer\u2019s disease studies. Mol Neurobiol 56:7355\u20137367. https:\/\/doi.org\/10.1007\/s12035-019-1605-3","journal-title":"Mol Neurobiol"},{"key":"5149_CR87","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-62703-640-5_2","volume-title":"Neuronal Cell Culture","author":"J Kovalevich","year":"2013","unstructured":"Kovalevich J, Langford D (2013) Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. In: Amini S, White MK (eds) Neuronal Cell Culture. Humana Press, Totowa, NJ, pp 9\u201321"},{"key":"5149_CR88","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/cbf.3317","volume":"36","author":"R Akki","year":"2018","unstructured":"Akki R, Siracusa R, Morabito R et al (2018) Neuronal-like differentiated SH-SY5Y cells adaptation to a mild and transient HO-induced oxidative stress. Cell Biochem Funct 36:56\u201364. https:\/\/doi.org\/10.1002\/cbf.3317","journal-title":"Cell Biochem Funct"},{"key":"5149_CR89","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/molecules30010115","volume":"30","author":"A Gumieniczek","year":"2024","unstructured":"Gumieniczek A, Berecka-Rycerz A, Dul M, Pryjda A (2024) Standardized chromatographic and computational approaches for lipophilicity analysis of five gliflozin antidiabetic drugs in relation to their biological activity. Molecules 30:115. https:\/\/doi.org\/10.3390\/molecules30010115","journal-title":"Molecules"},{"key":"5149_CR90","doi-asserted-by":"publisher","unstructured":"Ramdhani D, Listiani N, Sriyani ME et al (2023) Estrogen receptor targeting with genistein radiolabeled Technetium-99m as radiotracer of breast cancer: its optimization, characterization, and predicting stability constants by DFT calculation. Heliyon 9. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e13169","DOI":"10.1016\/j.heliyon.2023.e13169"},{"key":"5149_CR91","doi-asserted-by":"publisher","unstructured":"Gelder T van, Lerma E, Engelke K, Huizinga RB (2022) Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. Expert Rev Clin Pharmacol 15(5):515\u2013529. https:\/\/doi.org\/10.1080\/17512433.2022.2092470","DOI":"10.1080\/17512433.2022.2092470"},{"key":"5149_CR92","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3390\/biom10111556","volume":"10","author":"H Amat-ur-Rasool","year":"2020","unstructured":"Amat-ur-Rasool H, Symes F, Tooth D et al (2020) Potential nutraceutical properties of leaves from several commonly cultivated plants. Biomolecules 10:1556. https:\/\/doi.org\/10.3390\/biom10111556","journal-title":"Biomolecules"},{"key":"5149_CR93","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/brainsci11020184","volume":"11","author":"H Amat-ur-Rasool","year":"2021","unstructured":"Amat-ur-Rasool H, Ahmed M, Hasnain S, Carter WG (2021) Anti-cholinesterase combination drug therapy as a potential treatment for Alzheimer\u2019s disease. Brain Sci 11:184. https:\/\/doi.org\/10.3390\/brainsci11020184","journal-title":"Brain Sci"},{"key":"5149_CR94","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.3390\/ijms24032500","volume":"24","author":"A Kola","year":"2023","unstructured":"Kola A, Lamponi S, Curr\u00f2 F, Valensin D (2023) A comparative study between lycorine and galantamine abilities to interact with AMYLOID \u03b2 and reduce in vitro neurotoxicity. IJMS 24:2500. https:\/\/doi.org\/10.3390\/ijms24032500","journal-title":"IJMS"},{"key":"5149_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284994","volume":"18","author":"M Girgin","year":"2023","unstructured":"Girgin M, Isik S, Kantarci-Carsibasi N (2023) Proposing novel natural compounds against Alzheimer\u2019s disease targeting acetylcholinesterase. PLoS ONE 18:e0284994. https:\/\/doi.org\/10.1371\/journal.pone.0284994","journal-title":"PLoS ONE"},{"key":"5149_CR96","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.3390\/molecules29184365","volume":"29","author":"KA Wojtunik-Kulesza","year":"2024","unstructured":"Wojtunik-Kulesza KA, Rudkowska M, Klimek K et al (2024) S-(+)-Carvone, a Monoterpene with Potential Anti-Neurodegenerative Activity\u2014In Vitro, In Vivo and Ex Vivo Studies. Molecules 29:4365. https:\/\/doi.org\/10.3390\/molecules29184365","journal-title":"Molecules"},{"key":"5149_CR97","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1248\/cpb.c16-00221","volume":"64","author":"S Parlar","year":"2016","unstructured":"Parlar S, Bayraktar G, Tarikogullari AH et al (2016) Synthesis, biological evaluation and molecular docking study of hydrazone-containing pyridinium salts as cholinesterase inhibitors. Chem Pharm Bull 64:1281\u20131287. https:\/\/doi.org\/10.1248\/cpb.c16-00221","journal-title":"Chem Pharm Bull"},{"key":"5149_CR98","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/molecules24030446","volume":"24","author":"N Kowal","year":"2019","unstructured":"Kowal N, Indurthi D, Ahring P et al (2019) Novel approach for the search for chemical scaffolds with activity at both acetylcholinesterase and the \u03b17 nicotinic acetylcholine receptor: a perspective on scaffolds with dual activity for the treatment of neurodegenerative disorders. Molecules 24:446. https:\/\/doi.org\/10.3390\/molecules24030446","journal-title":"Molecules"},{"key":"5149_CR99","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1021\/acs.jnatprod.2c01150","volume":"86","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Xu J-B, Xiao Y et al (2023) Palladium-catalyzed synthesis, acetylcholinesterase inhibition, and neuroprotective activities of n-aryl galantamine analogues. J Nat Prod 86:939\u2013946. https:\/\/doi.org\/10.1021\/acs.jnatprod.2c01150","journal-title":"J Nat Prod"},{"key":"5149_CR100","doi-asserted-by":"publisher","first-page":"40180","DOI":"10.1074\/jbc.M110.142356","volume":"285","author":"K Takata","year":"2010","unstructured":"Takata K, Kitamura Y, Saeki M et al (2010) Galantamine-induced amyloid-\u03b2 clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285:40180\u201340191. https:\/\/doi.org\/10.1074\/jbc.M110.142356","journal-title":"J Biol Chem"},{"key":"5149_CR101","doi-asserted-by":"publisher","unstructured":"Roy S, Awasthi H (2017) Herbal medicines as neuroprotective agent: a mechanistic approach. Int J Pharm Pharm Sci 9:1. https:\/\/doi.org\/10.22159\/ijpps.2017v9i11.19444","DOI":"10.22159\/ijpps.2017v9i11.19444"},{"key":"5149_CR102","first-page":"137","volume-title":"Akaike A","author":"S Shimohama","year":"2018","unstructured":"Shimohama S, Kawamata J (2018) Roles of nicotinic acetylcholine receptors in the pathology and treatment of Alzheimer\u2019s and Parkinson\u2019s diseases. In: Shimohama S, Misu Y (eds) Akaike A. Springer Singapore, Singapore, pp 137\u2013158"},{"key":"5149_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7299778","volume":"2022","author":"B Aryal","year":"2022","unstructured":"Aryal B, Raut BK, Bhattarai S et al (2022) Potential therapeutic applications of plant-derived alkaloids against inflammatory and neurodegenerative diseases. Evid Based Complement Alternat Med 2022:1\u201318. https:\/\/doi.org\/10.1155\/2022\/7299778","journal-title":"Evid Based Complement Alternat Med"},{"key":"5149_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.890015","volume":"17","author":"N Zaghloul","year":"2023","unstructured":"Zaghloul N, Cohen NS, Ayasolla KR et al (2023) Galantamine ameliorates hyperoxia-induced brain injury in neonatal mice. Front Neurosci 17:890015. https:\/\/doi.org\/10.3389\/fnins.2023.890015","journal-title":"Front Neurosci"},{"key":"5149_CR105","doi-asserted-by":"publisher","first-page":"12092","DOI":"10.3390\/ijms232012092","volume":"23","author":"V Campos-Pe\u00f1a","year":"2022","unstructured":"Campos-Pe\u00f1a V, Pichardo-Rojas P, S\u00e1nchez-Barbosa T et al (2022) Amyloid \u03b2, lipid metabolism, basal cholinergic system, and therapeutics in Alzheimer\u2019s disease. IJMS 23:12092. https:\/\/doi.org\/10.3390\/ijms232012092","journal-title":"IJMS"},{"key":"5149_CR106","doi-asserted-by":"publisher","unstructured":"Alag\u00f6z F (2020) Influence of galantamine on peripheral nerve degeneration after experimental compression injury of the rat sciatic nerve. Ulus Travma Acil Cerrahi Derg. https:\/\/doi.org\/10.14744\/tjtes.2020.56573","DOI":"10.14744\/tjtes.2020.56573"},{"key":"5149_CR107","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/10715762.2011.567984","volume":"45","author":"K Fukui","year":"2011","unstructured":"Fukui K, Takatsu H, Koike T, Urano S (2011) Hydrogen peroxide induces neurite degeneration: prevention by tocotrienols. Free Radical Res 45:681\u2013691. https:\/\/doi.org\/10.3109\/10715762.2011.567984","journal-title":"Free Radical Res"},{"key":"5149_CR108","first-page":"49","volume":"3","author":"S Khoramian Tusi","year":"2012","unstructured":"Khoramian Tusi S, Babaei Abraki S, Amini M, Khodagholi F (2012) Modulation of H2O2-induced neurite outgrowth impairment and apoptosis in PC12 cells by a 1,2,4-triazine derivative. Basic Clin Neurosci 3:49\u201360","journal-title":"Basic Clin Neurosci"},{"key":"5149_CR109","doi-asserted-by":"publisher","unstructured":"Kocanci FG, Hamamcioglu B, Aslim B (2022) The relationship between neuroprotective activity and antigenotoxic and acetylcholinesterase inhibitory effects of Glaucium corniculatum extracts. Braz J Pharm Sci 58. https:\/\/doi.org\/10.1590\/s2175-97902022e19472","DOI":"10.1590\/s2175-97902022e19472"},{"key":"5149_CR110","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.brainres.2005.01.017","volume":"1038","author":"S Man\u00e1kov\u00e1","year":"2005","unstructured":"Man\u00e1kov\u00e1 S, Singh A, K\u00e4\u00e4ri\u00e4inen T et al (2005) Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. Brain Res 1038:83\u201391. https:\/\/doi.org\/10.1016\/j.brainres.2005.01.017","journal-title":"Brain Res"},{"key":"5149_CR111","doi-asserted-by":"publisher","unstructured":"Pyrzynska B, Serrano M, Mart\u0131\u0301nez AC, Kaminska B (2002) Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin A. J Biol Chem 277:14102\u201314108. https:\/\/doi.org\/10.1074\/jbc.M104443200","DOI":"10.1074\/jbc.M104443200"},{"key":"5149_CR112","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1096\/fasebj.13.12.1611","volume":"13","author":"AR Alexanian","year":"1999","unstructured":"Alexanian AR, Bamburg JR (1999) Neuronal survival activity of S100\u03b2\u03b2 is enhanced by calcineurin inhibitors and requires activation of NF-\u03baB. FASEB J 13:1611\u20131620. https:\/\/doi.org\/10.1096\/fasebj.13.12.1611","journal-title":"FASEB J"},{"key":"5149_CR113","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.redox.2017.04.004","volume":"12","author":"A Garcimart\u00edn","year":"2017","unstructured":"Garcimart\u00edn A, L\u00f3pez-Oliva ME, Gonz\u00e1lez MP et al (2017) Hydrogen peroxide modifies both activity and isoforms of acetylcholinesterase in human neuroblastoma SH-SY5Y cells. Redox Biol 12:719\u2013726. https:\/\/doi.org\/10.1016\/j.redox.2017.04.004","journal-title":"Redox Biol"},{"key":"5149_CR114","doi-asserted-by":"publisher","unstructured":"Chetsawang J, Govitrapong P, Chetsawang B (2010) Hydrogen peroxide toxicity induces ras signaling in human neuroblastoma SH-SY5Y cultured cells.\u00a0J Biomed Biotechnol 2010. https:\/\/doi.org\/10.1155\/2010\/803815","DOI":"10.1155\/2010\/803815"},{"key":"5149_CR115","doi-asserted-by":"publisher","unstructured":"Zhu H, Gao W, Jiang H et al (2007) Calcineurin mediates acetylcholinesterase expression during calcium ionophore A23187-induced HeLa cell apoptosis.\u00a0Biochim Biophys Acta Mol Cell Res\u00a01773:593\u2013602. https:\/\/doi.org\/10.1016\/j.bbamcr.2007.01.008","DOI":"10.1016\/j.bbamcr.2007.01.008"},{"key":"5149_CR116","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0026-895X(24)12764-2","volume":"56","author":"ZD Luo","year":"1999","unstructured":"Luo ZD, Wang Y, Werlen G et al (1999) Calcineurin enhances acetylcholinesterase mRNA stability during C2\u2013C12 muscle cell differentiation. Mol Pharmacol 56:886\u2013894. https:\/\/doi.org\/10.1016\/S0026-895X(24)12764-2","journal-title":"Mol Pharmacol"},{"key":"5149_CR117","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.3390\/cells12202440","volume":"12","author":"A Kale","year":"2023","unstructured":"Kale A, Shelke V, Lei Y et al (2023) Voclosporin: unique chemistry, pharmacology and toxicity profile, and possible options for implementation into the management of lupus nephritis. Cells 12:2440. https:\/\/doi.org\/10.3390\/cells12202440","journal-title":"Cells"},{"key":"5149_CR118","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1107\/S0907444910051905","volume":"67","author":"A Kuglstatter","year":"2011","unstructured":"Kuglstatter A, Mueller F, Kusznir E et al (2011) Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallogr D Biol Crystallogr 67:119\u2013123. https:\/\/doi.org\/10.1107\/S0907444910051905","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"5149_CR119","doi-asserted-by":"publisher","unstructured":"Li Y, Palmisano M, Sun D, Zhou S (2020) Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. Clin Pharmacol: Adv Appl 12:83\u201396. https:\/\/doi.org\/10.2147\/CPAA.S255789","DOI":"10.2147\/CPAA.S255789"},{"key":"5149_CR120","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ceca.2016.04.002","volume":"60","author":"A Magenta","year":"2016","unstructured":"Magenta A, Dellambra E, Ciarapica R, Capogrossi MC (2016) Oxidative stress, microRNAs and cytosolic calcium homeostasis. Cell Calcium 60:207\u2013217. https:\/\/doi.org\/10.1016\/j.ceca.2016.04.002","journal-title":"Cell Calcium"},{"key":"5149_CR121","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1038\/cddis.2013.533","volume":"5","author":"H He","year":"2014","unstructured":"He H, Liu X, Lv L et al (2014) Calcineurin suppresses AMPK-dependent cytoprotective autophagy in cardiomyocytes under oxidative stress. Cell Death Dis 5:e997\u2013e997. https:\/\/doi.org\/10.1038\/cddis.2013.533","journal-title":"Cell Death Dis"},{"key":"5149_CR122","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1582-4934.2009.00715.x","volume":"14","author":"KKW Hui","year":"2010","unstructured":"Hui KKW, Liadis N, Robertson J et al (2010) Calcineurin inhibition enhances motor neuron survival following injury. J Cellular Molecular Medi 14:671\u2013686. https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00715.x","journal-title":"J Cellular Molecular Medi"},{"key":"5149_CR123","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1523\/JNEUROSCI.20-19-07246.2000","volume":"20","author":"JE Springer","year":"2000","unstructured":"Springer JE, Azbill RD, Nottingham SA, Kennedy SE (2000) Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury. J Neurosci 20:7246\u20137251. https:\/\/doi.org\/10.1523\/JNEUROSCI.20-19-07246.2000","journal-title":"J Neurosci"},{"key":"5149_CR124","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1582-4934.2004.tb00259.x","volume":"8","author":"B Kaminska","year":"2004","unstructured":"Kaminska B, Gaweda-Walerych K, Zawadzka M (2004) Molecular mechanisms of neuroprotective action of immunosuppressants - facts and hypotheses. J Cellular Molecular Medi 8:45\u201358. https:\/\/doi.org\/10.1111\/j.1582-4934.2004.tb00259.x","journal-title":"J Cellular Molecular Medi"},{"key":"5149_CR125","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00109-012-0925-9","volume":"90","author":"M Zawadzka","year":"2012","unstructured":"Zawadzka M, Dabrowski M, Gozdz A et al (2012) Early steps of microglial activation are directly affected by neuroprotectant FK506 in both in vitro inflammation and in rat model of stroke. J Mol Med (Berl) 90:1459\u20131471. https:\/\/doi.org\/10.1007\/s00109-012-0925-9","journal-title":"J Mol Med (Berl)"},{"key":"5149_CR126","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1756-6606-2-33","volume":"2","author":"JR Pineda","year":"2009","unstructured":"Pineda JR, Pardo R, Zala D et al (2009) Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington\u2019s disease. Mol Brain 2:33. https:\/\/doi.org\/10.1186\/1756-6606-2-33","journal-title":"Mol Brain"},{"key":"5149_CR127","doi-asserted-by":"publisher","unstructured":"Herink J, Krej\u010dov\u00e1 G, Bajgar J (2002) Antiacetylcholinesterase activity of cyclosporine \u2013 a comparison of single and repeated administration and effect of 7-methoxytacrine. Acta Med (Hradec Kralove, Czech Repub) 45:145\u2013147. https:\/\/doi.org\/10.14712\/18059694.2019.71","DOI":"10.14712\/18059694.2019.71"},{"key":"5149_CR128","doi-asserted-by":"crossref","unstructured":"Cunha-Oliveira T, Lusa I, Cristina A (2012) Consequences of mitochondrial dysfunction in huntington\u2019s disease and protection via phosphorylation pathways. In: Ersoy Tunal N (ed). InTech","DOI":"10.5772\/32728"},{"key":"5149_CR129","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1523\/JNEUROSCI.4182-06.2007","volume":"27","author":"P Pregelj","year":"2007","unstructured":"Pregelj P, Trinkaus M, Zupan D et al (2007) The role of muscle activation pattern and calcineurin in acetylcholinesterase regulation in rat skeletal muscles. J Neurosci 27:1106\u20131113. https:\/\/doi.org\/10.1523\/JNEUROSCI.4182-06.2007","journal-title":"J Neurosci"},{"key":"5149_CR130","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.3390\/ijms21249591","volume":"21","author":"YJ Kang","year":"2020","unstructured":"Kang YJ, Diep YN, Tran M, Cho H (2020) Therapeutic targeting strategies for early- to late-staged Alzheimer\u2019s disease. IJMS 21:9591. https:\/\/doi.org\/10.3390\/ijms21249591","journal-title":"IJMS"},{"key":"5149_CR131","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/clpt.2011.77","volume":"90","author":"A Matas","year":"2011","unstructured":"Matas A (2011) Calcineurin inhibitors: short-term friend, long-term foe? Clin Pharmacol Ther 90:209\u2013211. https:\/\/doi.org\/10.1038\/clpt.2011.77","journal-title":"Clin Pharmacol Ther"},{"key":"5149_CR132","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/pharmaceutics16010048","volume":"16","author":"J Kim","year":"2023","unstructured":"Kim J, Shin S-A, Lee CS, Chung HJ (2023) An improved In vitro blood-brain barrier model for the evaluation of drug permeability using transwell with shear stress. Pharmaceutics 16:48. https:\/\/doi.org\/10.3390\/pharmaceutics16010048","journal-title":"Pharmaceutics"},{"key":"5149_CR133","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.3390\/ijms20133210","volume":"20","author":"W Zhang","year":"2019","unstructured":"Zhang W, Egashira N, Masuda S (2019) Recent topics on The mechanisms of immunosuppressive therapy-related neurotoxicities. IJMS 20:3210. https:\/\/doi.org\/10.3390\/ijms20133210","journal-title":"IJMS"},{"key":"5149_CR134","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12964-017-0203-0","volume":"15","author":"A Lombardi","year":"2017","unstructured":"Lombardi A, Trimarco B, Iaccarino G, Santulli G (2017) Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure. Cell Commun Signal 15:47. https:\/\/doi.org\/10.1186\/s12964-017-0203-0","journal-title":"Cell Commun Signal"},{"key":"5149_CR135","doi-asserted-by":"publisher","unstructured":"Seong JH, Park WY, Paek JH et al (2019) Impact of calcineurin inhibitors on rat glioma cells viability. Yeungnam Univ J Med 36:105\u2013108. https:\/\/doi.org\/10.12701\/yujm.2019.00108","DOI":"10.12701\/yujm.2019.00108"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05149-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05149-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05149-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:13:13Z","timestamp":1761570793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05149-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":135,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["5149"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05149-0","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}